Hims & Hers Abandons Wegovy-Style Semaglutide Pill After FDA Warning
Hims & Hers has scrapped its planned launch of a semaglutide-based weight loss pill designed to replicate Novo Nordisk’s Wegovy after the FDA warned it would enforce against unapproved GLP-1 generics. The move removes a key potential revenue driver from its growth pipeline.
1. Decision to Halt Semaglutide Copy
Hims & Hers ceased development of its semaglutide-based weight loss pill following FDA advisories that unapproved generics of GLP-1 therapies would face regulatory enforcement. The company had positioned the knockoff as a low-cost alternative to Wegovy to capture market share in the growing obesity treatment segment.
2. Impact on Growth Pipeline
By dropping the knockoff, Hims & Hers removes its sole in-house GLP-1 candidate, delaying its entry into the multibillion-dollar weight loss market. Analysts had modeled this product as a significant revenue contributor in 2026, forcing the firm to revise near-term growth projections.
3. Regulatory Environment and Next Steps
The FDA’s intensified scrutiny of semaglutide analogs underscores stricter compliance requirements for new obesity drugs, extending approval timelines and development costs. Hims & Hers is evaluating alternate strategies, including potential licensing deals or acquisitions, to rebuild its metabolic therapy pipeline.